Literature DB >> 29026382

Role of plasma adiponectin /C-reactive protein ratio in obesity and type 2 diabetes among African Americans.

Preetha Anna Abraham1, Selasi Attipoe1, Josh B Kazman1, Stacey Anne Zeno1, Merrily Poth1, Patricia Anne Deuster1.   

Abstract

BACKGROUND: Obesity is a modifiable risk factor for hypertension and T2D. Objective(s): We examined relations between fasting plasma adiponectin (ADIP), C-reactive protein (CRP) concentrations and markers of T2D in African Americans (AA).
METHODS: Fasting plasma ADIP, CRP, Insulin (IN), HOMA-IR, lipid profiles, body fat percent (%BF), waist circumference (WC), body mass index (BMI) and blood pressure measures were determined in AA women (W: n=77) and men (M: n=34). Participants were classified into: 1) Normal fasting glucose (FG) and Normal %BF; 2) Normal FG and High %BF; and 3) High FG.
RESULTS: Compared to men, women had significantly higher mean ADIP (W: 31.4±2.9 vs. M: 18.0±4.4 ng/L), CRP (W: 3.2±0.3 vs. M: 2.0±0.5 mg/L), %BF (W: 41.2±0.9 vs. M: 27.2±1.3), and BMI (W: 32.3±0.7 vs. M: 29.2±1.1 kg/m2). Women with normal FG and %BF had significantly higher ADIP (64.0±6.0) and lower CRP (1.3±0.6) concentrations than normal FG/ high %BF (ADIP: 37.0±5.0 and CRP: 3.1 ±0.5) and high FG (ADIP: 15.1±4.1 and CRP: 4.0 ± 0.5) groups. Women with high ADIP to CRP ratio had favorable metabolic and anthropometric profiles.
CONCLUSION: Low ADIP and high CRP are associated with excessive %BF and FG in AA women. ADIP/CRP, may be useful for detecting metabolic dysregulation.

Entities:  

Keywords:  Obesity; inflammation; type 2 diabetes

Mesh:

Substances:

Year:  2017        PMID: 29026382      PMCID: PMC5636261          DOI: 10.4314/ahs.v17i1.13

Source DB:  PubMed          Journal:  Afr Health Sci        ISSN: 1680-6905            Impact factor:   0.927


  49 in total

1.  Paradoxically high adiponectin and the healthy obese phenotype in obese black and white 16-year-old girls.

Authors:  John A Morrison; Charles J Glueck; Stephen Daniels; Ping Wang; Paul Horn; Davis Stroop
Journal:  Transl Res       Date:  2010-09-08       Impact factor: 7.012

2.  Inverse association between adiponectin and C-reactive protein in substantially healthy Japanese men.

Authors:  Kunihiro Matsushita; Hiroshi Yatsuya; Koji Tamakoshi; Keiko Wada; Rei Otsuka; Huiming Zhang; Kaichiro Sugiura; Takahisa Kondo; Toyoaki Murohara; Hideaki Toyoshima
Journal:  Atherosclerosis       Date:  2005-12-01       Impact factor: 5.162

3.  Sex-specific determinants of serum adiponectin in older adults: the role of endogenous sex hormones.

Authors:  G A Laughlin; E Barrett-Connor; S May
Journal:  Int J Obes (Lond)       Date:  2006-07-04       Impact factor: 5.095

4.  Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group.

Authors:  M N Ghazzi; J E Perez; T K Antonucci; J H Driscoll; S M Huang; B W Faja; R W Whitcomb
Journal:  Diabetes       Date:  1997-03       Impact factor: 9.461

5.  Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. 1999.

Authors:  Yukio Arita; Shinji Kihara; Noriyuki Ouchi; Masahiko Takahashi; Kazuhisa Maeda; Jun-ichiro Miyagawa; Kikuko Hotta; Iichiro Shimomura; Tadashi Nakamura; Koji Miyaoka; Hiroshi Kuriyama; Makoto Nishida; Shizuya Yamashita; Kosaku Okubo; Kenji Matsubara; Masahiro Muraguchi; Yasuichi Ohmoto; Tohru Funahashi; Yuji Matsuzawa
Journal:  Biochem Biophys Res Commun       Date:  2012-08-31       Impact factor: 3.575

6.  Gender and C-reactive protein: data from the Multiethnic Study of Atherosclerosis (MESA) cohort.

Authors:  Susan G Lakoski; Mary Cushman; Michael Criqui; Tatjana Rundek; Roger S Blumenthal; Ralph B D'Agostino; David M Herrington
Journal:  Am Heart J       Date:  2006-09       Impact factor: 4.749

7.  The relationship between C-reactive protein and other cardiovascular risk factors in men and women.

Authors:  Ross Arena; James A Arrowood; Ding-Yu Fei; Shirley Helm; Kenneth A Kraft
Journal:  J Cardiopulm Rehabil       Date:  2006 Sep-Oct       Impact factor: 2.081

8.  Gender differences in association of plasma adiponectin with obesity reflect resultant insulin resistance in non-diabetic Japanese patients with schizophrenia.

Authors:  Yukihiko Matsuda; Tetsuya Tanioka; Takaoki Yoshioka; Takamasa Nagano; Tadashi Hiroi; Kenichi Yoshikawa; Ken-Ichiro Okabe; Isao Nagamine; Yoichiro Takasaka
Journal:  Psychiatry Clin Neurosci       Date:  2005-06       Impact factor: 5.188

9.  The "metabolically-obese," normal-weight individual.

Authors:  N B Ruderman; S H Schneider; P Berchtold
Journal:  Am J Clin Nutr       Date:  1981-08       Impact factor: 7.045

10.  Adipocytokine profile of type 2 diabetics in metabolic syndrome as defined by various criteria.

Authors:  Nasser M Al-Daghri; Omar S Al-Attas; Khalid Al-Rubeaan; Reem Sallam
Journal:  Diabetes Metab Res Rev       Date:  2008 Jan-Feb       Impact factor: 4.876

View more
  3 in total

1.  Effect of very low-calorie ketogenic diet in combination with omega-3 on inflammation, satiety hormones, body composition, and metabolic markers. A pilot study in class I obese subjects.

Authors:  Mariangela Rondanelli; Simone Perna; Zahra Ilyas; Gabriella Peroni; Philip Bazire; Ignacio Sajuox; Roberto Maugeri; Mara Nichetti; Clara Gasparri
Journal:  Endocrine       Date:  2021-09-16       Impact factor: 3.633

2.  Short-Term Physiological Effects of a Very Low-Calorie Ketogenic Diet: Effects on Adiponectin Levels and Inflammatory States.

Authors:  Vincenzo Monda; Rita Polito; Annarita Lovino; Antonio Finaldi; Anna Valenzano; Ersilia Nigro; Gaetano Corso; Francesco Sessa; Alessio Asmundo; Nunzio Di Nunno; Giuseppe Cibelli; Giovanni Messina
Journal:  Int J Mol Sci       Date:  2020-05-02       Impact factor: 5.923

3.  Increased Adipose Tissue Expression of Interferon Regulatory Factor (IRF)-5 in Obesity: Association with Metabolic Inflammation.

Authors:  Sardar Sindhu; Reeby Thomas; Shihab Kochumon; Ajit Wilson; Mohamed Abu-Farha; Abdullah Bennakhi; Fahd Al-Mulla; Rasheed Ahmad
Journal:  Cells       Date:  2019-11-11       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.